Meeting to be held in London on October 8-9 hosted by Piper Sandler.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Positive Outlook on BridgeBio Pharma Driven by Promising Pipeline and Strategic Initiatives
- BridgeBio presented data from ATTRibute-CM study on acoramidis
- BridgeBio participates in a conference call with Piper Sandler
- Positive Buy Rating for BridgeBio Pharma’s Encaleret Driven by Promising Phase 2 Results and Significant Market Potential
- BridgeBio price target raised to $82 from $72 at UBS